@article{cc82c7ce81974ddf8585a170415b23c1,
title = "UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment",
author = "Lorenz Bastian and Hartmann, \{Alina M\} and Thomas Beder and Sonja H{\"a}nzelmann and Jan K{\"a}ssens and Miriam Bultmann and Hoeppner, \{Marc P\} and S{\"o}ren Franzenburg and Michael Wittig and Andre Franke and Inga Nagel and Malte Spielmann and Niklas Reimer and Hauke Busch and Stefan Schwartz and Bj{\"o}rn Steffen and Andreas Viardot and Konstanze D{\"o}hner and Mustafa Kondakci and Gerald Wulf and Knut Wendelin and Andrea Renzelmann and Alexander Kiani and Heiko Trautmann and Martin Neumann and Nicola G{\"o}kbuget and Monika Br{\"u}ggemann and Baldus, \{Claudia D\}",
note = "Funding Information: This study was in part funded by funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project number 444949889 (KFO 5010/1 Clinical Research Unit {\textquoteleft}CATCH ALL{\textquoteright} to LB, AH, MPH, MN, MBr, and CDB), Deutsche Jose Carreras Leuk{\"a}mie Stiftung (DJCLS 01R/2016 to LB and CDB). Funding Information: MBr received personal fees from Incyte (advisory board) and Roche Pharma AG, financial support for reference diagnostics from Affimed and Regeneron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), and personal fees from Janssen (speakers bureau), all outside the submitted work. The remaining authors declare no competing financial interests. None of the remaining authors has a relevant conflict of interest.",
year = "2022",
month = jun,
doi = "10.1038/s41375-022-01557-6",
language = "English",
volume = "36",
pages = "1676--1680",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Springer Nature",
number = "6",
}
SDG 3 – Gesundheit und Wohlergehen
SDG 9 – Industrie, Innovation und Infrastruktur
SDG 10 – Weniger Ungleichheiten